Critical Contrast: Lucid Diagnostics (NASDAQ:LUCD) vs. Nuvation Bio (NYSE:NUVB)

Lucid Diagnostics (NASDAQ:LUCD) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Lucid Diagnostics and Nuvation Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Nuvation Bio	1	2	9	0	2.67

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 904.20%. Nuvation Bio has a consensus price target of $12.89, indicating a potential upside of 196.64%. Given Lucid Diagnostics’ higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Nuvation Bio.

Institutional & Insider Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Lucid Diagnostics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Profitability

This table compares Lucid Diagnostics and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Nuvation Bio	-67.38%	-45.69%	-18.54%

Valuation & Earnings

This table compares Lucid Diagnostics and Nuvation Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.45 million	15.57	-$58.01 million	($0.47)	-0.89
Nuvation Bio	$201.73 million	7.56	-$204.63 million	($0.40)	-10.86

Lucid Diagnostics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Nuvation Bio beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.